Get the Stockscreener App
1.99
2.58%
0.05
Pre-market:
1.99
Biomea Fusion Inc stock is traded at $1.99, with a volume of 1.55M.
It is up +2.58% in the last 24 hours and up +34.46% over the past month.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
See More
Previous Close:
$1.94
Open:
$1.9
24h Volume:
1.55M
Relative Volume:
0.79
Market Cap:
$95.06M
Revenue:
-
Net Income/Loss:
$-144.01M
P/E Ratio:
-0.4963
EPS:
-4.01
Net Cash Flow:
$-113.02M
1W Performance:
+4.19%
1M Performance:
+34.46%
6M Performance:
-51.23%
1Y Performance:
-55.28%
1-Day Range:
$1.815
$1.99
1-Week Range:
$1.63
$1.99
52-Week Range:
$1.2905
$13.07
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
900 MIDDLEFIELD ROAD, REDWOOD CITY
Compare BMEA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.99 | 95.06M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-25 | Resumed | Piper Sandler | Overweight |
| Oct-09-24 | Initiated | Edward Jones | Buy |
| Sep-27-24 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Sep-27-24 | Upgrade | Truist | Hold → Buy |
| Aug-29-24 | Initiated | CapitalOne | Overweight |
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
Market Today: Safran's Asset Sale and Biomea Fusion's Stock Offering - GuruFocus
Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga
Top Midday Decliners - MarketScreener
Biomea Fusion stock falls after announcing public offering By Investing.com - Investing.com South Africa
Biomea Fusion stock falls after announcing public offering - Investing.com Australia
Biomea Fusion (BMEA) Reports Promising Preclinical Results for W - GuruFocus
Bitdeer, Biomea Fusion, Circle Internet - TradingView
Biomea Fusion (BMEA) Reports Promising Preclinical Results for Weight Loss Study | BMEA Stock News - GuruFocus
Biomea Fusion Reports Preclinical Data for BMF-650, a - GlobeNewswire
Biomea Fusion (BMEA) Receives Reaffirmed Buy Rating by D. Boral Capital | BMEA Stock News - GuruFocus
Biomea Fusion surges 76% following InvestingPro’s April Fair Value alert By Investing.com - Investing.com India
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates - Yahoo Finance
US Stocks Likely To Open Higher Despite Trump's 'Unconditional Surrender' Call: All Eyes On Powell As Experts Predict Inflation Will Limit Fed's Rate Cut Capacity - Benzinga
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Biomea Fusion tumbles on deep-discounted $40 mln equity raise - TradingView
Biomea Fusion Prices $40 Million Offering of Securities - marketscreener.com
Biomea Fusion (BMEA) Launches Public Offering with Warrants | BM - GuruFocus
Biomea Fusion (BMEA) Launches $40M Public Offering, Shares Drop - GuruFocus
Biomea Fusion sinks 25%, prices $40M stock offering (BMEA:NASDAQ) - Seeking Alpha
Diabetes Drug Developer Biomea Fusion Raises $40M in Strategic Public Offering with Warrant Sweetener - Stock Titan
(BMEA) Faces Pricing Challenge with New Offering | BMEA Stock News - GuruFocus
Biomea Fusion Slides After-Hours Following Stock-And-Warrant Offering; Retail Traders See Rebound Ahead - Asianet Newsable
Biomea Fusion Announces Pricing Of Public Offering Of Securities - marketscreener.com
Biomea Fusion Announces Pricing of Public Offering of Securities - GlobeNewswire Inc.
Biomea Fusion launches public offering of common stock and warrants By Investing.com - Investing.com India
Biomea Fusion Launches Public Offering of Securities; Shares Fall After Hours - marketscreener.com
Biomea Fusion tumbles on planned equity offering - TradingView
Biomea Fusion launches public offering of common stock and warrants - Investing.com
Biomea Fusion Announces Proposed Public Offering of Securities - GlobeNewswire
Biomea Fusion, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants - Nasdaq
Biomea Fusion Launches Major Public Offering with Jefferies to Advance Diabetes and Obesity Programs - Stock Titan
Biomea Fusion stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
Biomea Fusion, Inc. (NASDAQ:BMEA) Shares Purchased by Bank of America Corp DE - Defense World
D. Boral Capital Reiterates Buy Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
Biomea Fusion (BMEA) Receives Continued - GuruFocus
Biomea Fusion reports sustained responses in leukemia patients By Investing.com - Investing.com South Africa
Biomea Fusion (BMEA) Receives Continued "Buy" Rating from D. Bor - GuruFocus
Biomea Fusion (BMEA) Reveals Promising Clinical Data for Acute L - GuruFocus
Biomea Fusion reports sustained responses in leukemia patients - Investing.com Australia
Biomea Fusion (BMEA) Reveals Promising Clinical Data for Acute Leukemia Treatment | BMEA Stock News - GuruFocus
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 - The Manila Times
Biomea Fusion (BMEA) Sees Significant Indicative Borrow Rate Inc - GuruFocus
Largest borrow rate increases among liquid names - TipRanks
LUCA ANNOUNCES LEADERSHIP GROWTH AND BOARD TRANSITION - The Globe and Mail
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of “Buy” by Brokerages - Defense World
Wellington Management Group LLP Acquires Shares of 81,759 Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know - MSN
Biomea Fusion (NASDAQ:BMEA) Upgraded at Piper Sandler - Defense World
Biomea Fusion (NASDAQ:BMEA) Coverage Initiated by Analysts at Piper Sandler - Defense World
BMEABiomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights - mx.advfn.com
BMEA: Piper Sandler Initiates Coverage with Overweight Rating an - GuruFocus
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):